H. Thomas Karnes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
H. Thomas Karnes has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Sunil S. Iyer
Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298-0533, USA
6 shared publicationsMatthew S. Halquist
Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA
4 shared publicationsMichael C. Peoples
Department of Pharmaceutics, Virginia Commonwealth University Medical Center, P.O. Box 980533, Richmond, VA 23298-0533, United States
4 shared publications- Omnia Ahmed Ismaiel
Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA
4 shared publications Rand G. Jenkins
Chromatographic Sciences, PPD, 2244 Dabney Road, Richmond, VA 23230, USA
4 shared publications- Glen Eugene Kellogg
Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23298, USA
3 shared publications
Latest Publications
- 1 September 2015
- Published by Elsevier in Journal of Chromatography B
- Vol. 1001, 156-168
Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC–MS/MS
- 1 September 2015
- Published by Elsevier in Journal of Chromatography B
- Vol. 1001, 156-168
Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC–MS/MS
- 27 April 2015
- Published by Wiley in Biomedical Chromatography
- Vol. 29 (11) , 1780-1782
An extended stable isotope‐labeled signature peptide internal standard for tracking immunocapture of human plasma osteopontin for LC‐MS/MS quantification
A stable isotope‐labeled signature peptide, whose sequence corresponds to the human osteopontin (hOPN) specific antibody epitope, was evaluated as an internal standard to compensate for immunocapture variability during quantification of hOPN by immunoaffinity‐coupled LC‐MS/MS. Immunocapture variability was induced by varying the antibody amount per well from 150 to 4500 ng and analysis was carried out with internal standards added before and after the immunocapture step. The immunocapture variability ranged from −80.9 to 77.0% when the IS was added after immunocapture and from −37.5 to 20.3% when the internal standard was added before immunocapture. The lower variability demonstrates the ability of stable labeled isotope internal standard peptide to compensate for variation during immunocapture. Copyright © 2015 John Wiley & Sons, Ltd.
- 27 April 2015
- Published by Wiley in Biomedical Chromatography
- Vol. 29 (11) , 1780-1782
An extended stable isotope‐labeled signature peptide internal standard for tracking immunocapture of human plasma osteopontin for LC‐MS/MS quantification
A stable isotope‐labeled signature peptide, whose sequence corresponds to the human osteopontin (hOPN) specific antibody epitope, was evaluated as an internal standard to compensate for immunocapture variability during quantification of hOPN by immunoaffinity‐coupled LC‐MS/MS. Immunocapture variability was induced by varying the antibody amount per well from 150 to 4500 ng and analysis was carried out with internal standards added before and after the immunocapture step. The immunocapture variability ranged from −80.9 to 77.0% when the IS was added after immunocapture and from −37.5 to 20.3% when the internal standard was added before immunocapture. The lower variability demonstrates the ability of stable labeled isotope internal standard peptide to compensate for variation during immunocapture. Copyright © 2015 John Wiley & Sons, Ltd.
- 10 October 2012
- Published by Wiley in Drug Testing and Analysis
- Vol. 5 (8) , 710-715
Investigation of endogenous blood lipids components that contribute to matrix effects in dried blood spot samples by liquid chromatography‐tandem mass spectrometry
Dried blood spot (DBS) sampling coupled to liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a rapidly developing approach in the field of biopharmaceutical analysis. DBS sampling enables analysis of small sample volumes with high sensitivity and selectivity while providing a convenient easy to store and ship format. Lipid components that may be extracted during biological sample processing may result in matrix ionization effects and can significantly affect the precision and accuracy of the results. Glycerophosphocholines (GPChos), cholesterols and triacylglycerols (TAG) are the main lipid components that contribute to matrix effects in LC-MS/MS. Various organic solvents such as methanol, acetonitrile, methyl tertiary butyl ether, ethyl ether, dichloromethane and n-hexane were investigated for elution of these lipid components from DBS samples. Methanol extracts demonstrated the highest levels of GPChos whereas ethyl ether and n-hexane extracts contained less than 1.0 % of the GPChos levels in the methanol extracts. Ethyl ether extracts contained the highest levels of cholesterols and TAG in comparison to other investigated organic solvents. Acetonitrile is recommended as an elution solvent due to low lipid recoveries. Matrix effects resulted from different extracted lipid components should be studied and assessed carefully in DBS samples. Copyright © 2012 John Wiley & Sons, Ltd.
- 10 October 2012
- Published by Wiley in Drug Testing and Analysis
- Vol. 5 (8) , 710-715
Investigation of endogenous blood lipids components that contribute to matrix effects in dried blood spot samples by liquid chromatography‐tandem mass spectrometry
Dried blood spot (DBS) sampling coupled to liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a rapidly developing approach in the field of biopharmaceutical analysis. DBS sampling enables analysis of small sample volumes with high sensitivity and selectivity while providing a convenient easy to store and ship format. Lipid components that may be extracted during biological sample processing may result in matrix ionization effects and can significantly affect the precision and accuracy of the results. Glycerophosphocholines (GPChos), cholesterols and triacylglycerols (TAG) are the main lipid components that contribute to matrix effects in LC-MS/MS. Various organic solvents such as methanol, acetonitrile, methyl tertiary butyl ether, ethyl ether, dichloromethane and n-hexane were investigated for elution of these lipid components from DBS samples. Methanol extracts demonstrated the highest levels of GPChos whereas ethyl ether and n-hexane extracts contained less than 1.0 % of the GPChos levels in the methanol extracts. Ethyl ether extracts contained the highest levels of cholesterols and TAG in comparison to other investigated organic solvents. Acetonitrile is recommended as an elution solvent due to low lipid recoveries. Matrix effects resulted from different extracted lipid components should be studied and assessed carefully in DBS samples. Copyright © 2012 John Wiley & Sons, Ltd.
- 1 May 2011
- Published by Elsevier in Journal of Chromatography B
- Vol. 879 (15-16) , 1156
Corrigendum to “Investigation of endogenous blood plasma phospholipids, cholesterol and glycerides that contribute to matrix effects in bioanalysis by liquid chromatography/mass spectrometry” [J. Chromatogr. B 878 (2010) 3303]
- 1 May 2011
- Published by Elsevier in Journal of Chromatography B
- Vol. 879 (15-16) , 1156
Corrigendum to “Investigation of endogenous blood plasma phospholipids, cholesterol and glycerides that contribute to matrix effects in bioanalysis by liquid chromatography/mass spectrometry” [J. Chromatogr. B 878 (2010) 3303]
- 1 April 2011
- Published by Elsevier in Journal of Chromatography B
- Vol. 879 (11-12) , 789-798
Quantification of Alefacept, an immunosuppressive fusion protein in human plasma using a protein analogue internal standard, trypsin cleaved signature peptides and liquid chromatography tandem mass spectrometry
- 1 April 2011
- Published by Elsevier in Journal of Chromatography B
- Vol. 879 (11-12) , 789-798
Quantification of Alefacept, an immunosuppressive fusion protein in human plasma using a protein analogue internal standard, trypsin cleaved signature peptides and liquid chromatography tandem mass spectrometry
- 10 December 2010
- Published by Wiley in Biomedical Chromatography
- Vol. 25 (1-2) , 47-58
Quantitative liquid chromatography tandem mass spectrometry analysis of macromolecules using signature peptides in biological fluids
Targeted protein quantification using peptide surrogates has increasingly become important to the validation of biomarker candidates and development of protein therapeutics. These approaches have been proposed and employed as alternatives to immunoassays in biological fluids. Technological advances over the last 20 years in biochemistry and mass spectrometry have prompted the use of peptides as surrogates to quantify enzyme digested proteins using triple quadrupole mass spectrometers. Multiple sample preparation processes are often incorporated to achieve quantification of target proteins using these signature peptides. This review article focuses on these processes or hyphenated techniques for quantification of proteins with peptide surrogates. The most recent advances and strategies involved with hyphenated techniques are discussed. Copyright © 2010 John Wiley & Sons, Ltd.
- 10 December 2010
- Published by Wiley in Biomedical Chromatography
- Vol. 25 (1-2) , 47-58
Quantitative liquid chromatography tandem mass spectrometry analysis of macromolecules using signature peptides in biological fluids
Targeted protein quantification using peptide surrogates has increasingly become important to the validation of biomarker candidates and development of protein therapeutics. These approaches have been proposed and employed as alternatives to immunoassays in biological fluids. Technological advances over the last 20 years in biochemistry and mass spectrometry have prompted the use of peptides as surrogates to quantify enzyme digested proteins using triple quadrupole mass spectrometers. Multiple sample preparation processes are often incorporated to achieve quantification of target proteins using these signature peptides. This review article focuses on these processes or hyphenated techniques for quantification of proteins with peptide surrogates. The most recent advances and strategies involved with hyphenated techniques are discussed. Copyright © 2010 John Wiley & Sons, Ltd.
- 1 August 2009
- Published by Elsevier in Journal of Chromatography B
- Vol. 877 (23) , 2270-2274
A proposed “fixed” range decision criteria for transfer of bioanalytical methods
- 1 August 2009
- Published by Elsevier in Journal of Chromatography B
- Vol. 877 (23) , 2270-2274
A proposed “fixed” range decision criteria for transfer of bioanalytical methods
- 1 September 2008
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 48 (2) , 376-382
Demonstration of a direct capture immunoaffinity separation for C-reactive protein using a capillary-based microfluidic device
- 1 September 2008
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 48 (2) , 376-382
Demonstration of a direct capture immunoaffinity separation for C-reactive protein using a capillary-based microfluidic device
- 23 July 2008
- Published by Wiley in Biomedical Chromatography
- Vol. 22 (11) , 1272-1278
Assessment of matrix effects and determination of niacin in human plasma using liquid–liquid extraction and liquid chromatography–tandem mass spectrometry
A simple, sensitive and rapid liquid–liquid extraction method for the analysis of nicotinic acid (niacin) and its labeled internal standard nicotinic acid‐d4 (niacin‐d4) in human plasma was developed and validated. The analyte and its internal standard were isolated from acidified plasma using a single liquid–liquid extraction procedure with methyl‐t‐butyl ether. The extracted samples were analyzed by liquid chromatography–tandem mass spectrometry in positive electrospray ionization mode with multiple reaction monitoring. The calibration curves were linear in the measured range between 5 and 1000 ng/mL and the limit of detection was calculated as 122 pg/mL. The method required 250 µL of human plasma and the total run time between injections was 3.5 min. Matrix effects were assessed by post‐column infusion experiments, phospholipids monitoring and post‐extraction addition experiments. The extraction of phospholipids and niacin from plasma was studied under acidic, neutral and basic conditions. Acidic conditions were optimal for both the recovery of niacin and the removal of phospholipids; the degree of matrix effects for niacin was determined to be 2.5%. It was concluded that effective removal of matrix components can overcome low recovery issues associated with liquid–liquid extractions of polar analytes. Copyright © 2008 John Wiley & Sons, Ltd.
- 23 July 2008
- Published by Wiley in Biomedical Chromatography
- Vol. 22 (11) , 1272-1278
Assessment of matrix effects and determination of niacin in human plasma using liquid–liquid extraction and liquid chromatography–tandem mass spectrometry
A simple, sensitive and rapid liquid–liquid extraction method for the analysis of nicotinic acid (niacin) and its labeled internal standard nicotinic acid‐d4 (niacin‐d4) in human plasma was developed and validated. The analyte and its internal standard were isolated from acidified plasma using a single liquid–liquid extraction procedure with methyl‐t‐butyl ether. The extracted samples were analyzed by liquid chromatography–tandem mass spectrometry in positive electrospray ionization mode with multiple reaction monitoring. The calibration curves were linear in the measured range between 5 and 1000 ng/mL and the limit of detection was calculated as 122 pg/mL. The method required 250 µL of human plasma and the total run time between injections was 3.5 min. Matrix effects were assessed by post‐column infusion experiments, phospholipids monitoring and post‐extraction addition experiments. The extraction of phospholipids and niacin from plasma was studied under acidic, neutral and basic conditions. Acidic conditions were optimal for both the recovery of niacin and the removal of phospholipids; the degree of matrix effects for niacin was determined to be 2.5%. It was concluded that effective removal of matrix components can overcome low recovery issues associated with liquid–liquid extractions of polar analytes. Copyright © 2008 John Wiley & Sons, Ltd.